The DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.
High Density Lipoprotein Cholesterol and the Risk of All-Cause Mortality among U.S. Veterans
Open accessAbstract
Background and objectives: The relationship between HDL cholesterol and all-cause mortality in patients with kidney disease is not clear. We sought to characterize the relationship of HDL cholesterol and risk of death and examine the association by eGFR levels. Design, setting, participants, & measurements: We built a cohort of 1,764,986 men who were United States veterans with at least one eGFR between October of 2003 and September of 2004 and followed them until September of 2013 or death. Results: Patients with low HDL cholesterol and low eGFR had a higher burden of comorbid illnesses. Over a median of 9.1 years (interquartile range, 7.7–9.4 years), 26,247 (40.1%), 109,222 (32.3%), 152,625 (29.2%), 113,785 (28.5%), and 139,803 (31.8%) participants with HDL cholesterol ≤25, >25 to <34, ≥34 to ≤42, >42 to <50, and ≥50 mg/dl died. In adjusted survival models, compared with the referent group of patients with low HDL cholesterol (≤25 mg/dl), intermediate HDL cholesterol levels (>25 to <34, ≥34 to ≤42, and >42 to <50 mg/dl) were associated with lower risk of death across all levels of eGFR. The lower risk was partially abrogated in those with high HDL cholesterol (≥50 mg/dl), and the risk of death was similar to the referent category among those with eGFR<30 or ≥90 ml/min per 1.73 m 2 . Analysis by HDL cholesterol deciles and spline analyses suggest that the relationship between HDL cholesterol and death follows a U-shaped curve. There was a significant interaction between eGFR and HDL cholesterol in that lower eGFR attenuated the salutary association of HDL cholesterol and risk of death ( P for interaction <0.01). Presence of coronary artery disease attenuated the lower risk of high HDL cholesterol and all-cause mortality in those with eGFR≥60 ml/min per 1.73 m 2 ( P for interaction <0.05). Conclusions: Our results show a U-shaped relationship between HDL cholesterol and risk of all-cause mortality across all eGFR categories. The risk is modified by eGFR and cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A recent register study of more than 1 million US veterans found a U-shaped relationship between HDL-C and total mortality with 50 mg/dL (1.25 mmol/L) as the nadir associated with the lowest mortality [76].”
From Comparisons of the effects of different flaxseed products consumption on lipid profiles, inflammatory cytokines and anthropometric indices in patients with dyslipidemia related diseases: systematic review and a dose-response meta-analysis of randomized controlled trials (2021) · cites this paper as [76]
Experimental — accuracy not yet measuredIn the citing paper
“A recent register study of more than 1 million US veterans found a U-shaped relationship between HDL-C and total mortality with 50 mg/dL (1.25 mmol/L) as the nadir associated with the lowest mortality [5].”
From HDL cholesterol: reappraisal of its clinical relevance (2017) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data
Quan, H., Sundararajan, V., Halfon, P., Fong, A., Burnand, B., Luthi, J.-C., Saunders, L. D., Beck, C. A., Feasby, T. E., & Ghali, W. A. (2005) · Medical Care · doi:10.1097/01.mlr.0000182534.19832.83 · Cited by 10,669
A formula to estimate the approximate surface area if height and weight be known. 1916.
Bois, D. D., & Bois, E. F. D. (1989) · PubMed · Cited by 5,303
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064278 · Cited by 1,610
Muntner, P., Coresh, J., Smith, J. C., Eckfeldt, J., & Klag, M. J. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00165.x · Cited by 667
Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD
Xie, Y., Bowe, B. C., Li, T., Xian, H., Balasubramanian, S., & Al‐Aly, Z. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015121377 · Cited by 334
Self-citationSpeer, T., Rohrer, L., Blyszczuk, P., Shroff, R., Kuschnerus, K., Kränkel, N., Kania, G., Zewinger, S., Akhmedov, A., Shi, Y., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.02.009 · Cited by 310
Trevisan, R., Dodesini, A. R., & Lepore, G. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005121320 · Cited by 246
Dysfunctional High-Density Lipoprotein in Patients on Chronic Hemodialysis
Yamamoto, S., Yancey, P. G., Ikizler, T. A., Jerome, W. G., Kaseda, R., Cox, B. E., Bian, A., Shintani, A., Fogo, A. B., Linton, M. F., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.013 · Cited by 197
Flagged first, then by citations
1 of the 28 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Voight, 2012, Plasma HDL cholesterol and risk of myocardial infarction: A Mendelian randomisation study., Lancet, 380, 572, 10.1016/S0140-6736(12)60312-2 · DOI · Paper page
Cited by
Sorted by citations
Items 201–213 of 213
Hang, L., Zhou, J., Luo, Z., & Zhang, L. (2025) · Medicine · doi:10.1097/md.0000000000046397
Yang, C., Xia, H., Wan, M., Lu, Y., Xu, D., Yang, X., Yang, L., & Sun, G. (2021) · Figshare · doi:10.6084/m9.figshare.16786917
Yang, C., Xia, H., Wan, M., Lu, Y., Xu, D., Yang, X., Yang, L., & Sun, G. (2021) · Figshare · doi:10.6084/m9.figshare.16786932
Yang, C., Xia, H., Wan, M., Lu, Y., Xu, D., Yang, X., Yang, L., & Sun, G. (2021) · Figshare · doi:10.6084/m9.figshare.16786920
Wang, M.-C., Li, C.-I., Liu, C.-S., Lin, C.-H., Yang, S.-Y., Li, T.-C., & Lin, C. (2021) · Figshare · doi:10.6084/m9.figshare.17084036
Yang, C., Xia, H., Wan, M., Lu, Y., Xu, D., Yang, X., Yang, L., & Sun, G. (2021) · Figshare · doi:10.6084/m9.figshare.16786926
Yang, C., Xia, H., Wan, M., Lu, Y., Xu, D., Yang, X., Yang, L., & Sun, G. (2021) · Figshare · doi:10.6084/m9.figshare.16786929
yu, Y., Li, M., Huang, X., Zhou, W., Wang, T., Zhu, L., Ding, C., Tao, Y., Bao, H., & Cheng, X. (2020) · Figshare · doi:10.6084/m9.figshare.13233156
Yang, C., Xia, H., Wan, M., Lu, Y., Xu, D., Yang, X., Yang, L., & Sun, G. (2021) · Figshare · doi:10.6084/m9.figshare.16786923
cHDL reevaluado: nuevos conocimientos y nuevo potencial en la farmacología cardiovascular
Fernández-Olmo, R., Cordero, A., Albarrán, O. G., Miranda, J. L., & Badimón, L. (2026) · REC CardioClinics · doi:10.1016/j.rccl.2025.12.004
Low HDL and high HDL syndromes
Yamashita, S., & Matsuzawa, Y. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00305-8
O’Donovan, G., Afzal, S., Petermann-Rocha, F. E., Apolinar‐Jiménez, E., Medina, C., Kuri-Morales, P. A., Tapia‐Conyer, R., & Alegre-Díaz, J. (2026) · medRxiv · doi:10.64898/2026.09.24.26363978
Nigatie, M., Reta, M. A., Jemal, A., Gedfie, S., Kassahun, W. D., Gashaw, M., Ashagre, A., Alemu, B. B., Misganaw, T., Abebe, W., et al. (2026) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2026.100333
Metadata
- Authors
- Bowe, B., Xie, Y., Xian, H., Balasubramanian, S., Zayed, M. A., & Al-Aly, Z.
- Affiliations
- Clinical Epidemiology Center, Research and Education Service,
- Saint Louis University (US)
- Corresponding author
- Bowe, Benjamin
- Xie, Yan
- Xian, Hong
- Balasubramanian, Sumitra
- Zayed, Mohamed A.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2016-08-11
- Volume
- 11
- Issue
- 10
- Pages
- 1784-1793
- ISSN
- 1555-9041 (ISSN-L)
- 1555-905X
- PMC
- PMC5053782
- OpenAlex
- W2512996508
- Cited by
- 213
- References
- 28
- Citations by year
- 2026: 7 · 2025: 18 · 2024: 16 · 2023: 11 · 2022: 26 · 2021: 46 · 2020: 21 · 2019: 26 · 2018: 16 · 2017: 22 · 2016: 4
- FWCI
- 25.09
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Journal of the American Society of Nephrology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Keywords
- HDL cholesterol, all-cause mortality, estimated glomerular filtration rate, kidney disease, veterans, U-shaped relationship, coronary artery disease, comorbidities, mortality risk, lipid-lowering therapy, cardiovascular risk stratification, mortality prediction model, dialysis, mortality risk reduction
- MeSH terms
- Aged, Coronary Artery Disease, Female, Glomerular Filtration Rate, Heart Failure, Humans, Kidney Diseases, Cholesterol, HDL, Longitudinal Studies, Male, Middle Aged, Mortality, Risk Factors, United States, Veterans, Comorbidity, Survival Rate, Proportional Hazards Models
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
